Consistent with previous findings, a PAR2 inhibitor, P2pal-18S, and gefitinib cooperatively attenuating EGFR activation in PC-9 cells (Figure 1D), indicating a transactivation between PAR2 and EGFR in NSCLC cells. Here, F2RL1 is linked to non-small cell lung carcinoma.